Safety of Kidney Transplantation from Donors with HIV.

IF 96.2 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL New England Journal of Medicine Pub Date : 2024-10-17 DOI:10.1056/nejmoa2403733
Christine M Durand,Allan Massie,Sander Florman,Tao Liang,Meenakshi M Rana,Rachel Friedman-Moraco,Alexander Gilbert,Peter Stock,Sapna A Mehta,Shikha Mehta,Valentina Stosor,Marcus R Pereira,Michele I Morris,Jonathan Hand,Saima Aslam,Maricar Malinis,Ghady Haidar,Catherine B Small,Carlos A Q Santos,Joanna Schaenman,John Baddley,David Wojciechowski,Emily A Blumberg,Karthik Ranganna,Oluwafisayo Adebiyi,Nahel Elias,Jose A Castillo-Lugo,Emmanouil Giorgakis,Senu Apewokin,Diane Brown,Darin Ostrander,Yolanda Eby,Niraj Desai,Fizza Naqvi,Serena Bagnasco,Natasha Watson,Erica Brittain,Jonah Odim,Andrew D Redd,Aaron A R Tobian,Dorry L Segev,
{"title":"Safety of Kidney Transplantation from Donors with HIV.","authors":"Christine M Durand,Allan Massie,Sander Florman,Tao Liang,Meenakshi M Rana,Rachel Friedman-Moraco,Alexander Gilbert,Peter Stock,Sapna A Mehta,Shikha Mehta,Valentina Stosor,Marcus R Pereira,Michele I Morris,Jonathan Hand,Saima Aslam,Maricar Malinis,Ghady Haidar,Catherine B Small,Carlos A Q Santos,Joanna Schaenman,John Baddley,David Wojciechowski,Emily A Blumberg,Karthik Ranganna,Oluwafisayo Adebiyi,Nahel Elias,Jose A Castillo-Lugo,Emmanouil Giorgakis,Senu Apewokin,Diane Brown,Darin Ostrander,Yolanda Eby,Niraj Desai,Fizza Naqvi,Serena Bagnasco,Natasha Watson,Erica Brittain,Jonah Odim,Andrew D Redd,Aaron A R Tobian,Dorry L Segev,","doi":"10.1056/nejmoa2403733","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nKidney transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV is an emerging practice. It has been performed since 2016 under the U.S. congressional HIV Organ Policy Equity Act and is currently approved for research only. The Department of Health and Human Services is considering expanding the procedure to clinical practice, but data are limited to small case series that did not include donors without HIV as controls.\r\n\r\nMETHODS\r\nIn an observational study conducted at 26 U.S. centers, we compared transplantation of kidneys from deceased donors with HIV and donors without HIV to recipients with HIV. The primary outcome was a safety event (a composite of death from any cause, graft loss, serious adverse event, HIV breakthrough infection, persistent failure of HIV treatment, or opportunistic infection), assessed for noninferiority (margin for the upper bound of the 95% confidence interval, 3.00). Secondary outcomes included overall survival, survival without graft loss, rejection, infection, cancer, and HIV superinfection.\r\n\r\nRESULTS\r\nWe enrolled 408 transplantation candidates, of whom 198 received a kidney from a deceased donor; 99 received a kidney from a donor with HIV and 99 from a donor without HIV. The adjusted hazard ratio for the composite primary outcome was 1.00 (95% confidence interval [CI], 0.73 to 1.38), which showed noninferiority. The following secondary outcomes were similar whether the donor had HIV or not: overall survival at 1 year (94% vs. 95%) and 3 years (85% vs. 87%), survival without graft loss at 1 year (93% vs. 90%) and 3 years (84% vs. 81%), and rejection at 1 year (13% vs. 21%) and 3 years (21% vs. 24%). The incidence of serious adverse events, infections, surgical or vascular complications, and cancer was similar in the groups. The incidence of HIV breakthrough infection was higher among recipients of kidneys from donors with HIV (incidence rate ratio, 3.14; 95%, CI, 1.02 to 9.63), with one potential HIV superinfection among the 58 recipients in this group with sequence data and no persistent failures of HIV treatment.\r\n\r\nCONCLUSIONS\r\nIn this observational study of kidney transplantation in persons with HIV, transplantation from donors with HIV appeared to be noninferior to that from donors without HIV. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT03500315.).","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New England Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1056/nejmoa2403733","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND Kidney transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV is an emerging practice. It has been performed since 2016 under the U.S. congressional HIV Organ Policy Equity Act and is currently approved for research only. The Department of Health and Human Services is considering expanding the procedure to clinical practice, but data are limited to small case series that did not include donors without HIV as controls. METHODS In an observational study conducted at 26 U.S. centers, we compared transplantation of kidneys from deceased donors with HIV and donors without HIV to recipients with HIV. The primary outcome was a safety event (a composite of death from any cause, graft loss, serious adverse event, HIV breakthrough infection, persistent failure of HIV treatment, or opportunistic infection), assessed for noninferiority (margin for the upper bound of the 95% confidence interval, 3.00). Secondary outcomes included overall survival, survival without graft loss, rejection, infection, cancer, and HIV superinfection. RESULTS We enrolled 408 transplantation candidates, of whom 198 received a kidney from a deceased donor; 99 received a kidney from a donor with HIV and 99 from a donor without HIV. The adjusted hazard ratio for the composite primary outcome was 1.00 (95% confidence interval [CI], 0.73 to 1.38), which showed noninferiority. The following secondary outcomes were similar whether the donor had HIV or not: overall survival at 1 year (94% vs. 95%) and 3 years (85% vs. 87%), survival without graft loss at 1 year (93% vs. 90%) and 3 years (84% vs. 81%), and rejection at 1 year (13% vs. 21%) and 3 years (21% vs. 24%). The incidence of serious adverse events, infections, surgical or vascular complications, and cancer was similar in the groups. The incidence of HIV breakthrough infection was higher among recipients of kidneys from donors with HIV (incidence rate ratio, 3.14; 95%, CI, 1.02 to 9.63), with one potential HIV superinfection among the 58 recipients in this group with sequence data and no persistent failures of HIV treatment. CONCLUSIONS In this observational study of kidney transplantation in persons with HIV, transplantation from donors with HIV appeared to be noninferior to that from donors without HIV. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT03500315.).
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
艾滋病病毒感染者肾移植的安全性。
背景将感染人类免疫缺陷病毒(HIV)的供体的肾移植给感染 HIV 的受体是一种新兴的做法。根据美国国会《HIV 器官政策公平法案》,自 2016 年起开始实施,目前仅批准用于研究。美国卫生与公众服务部正在考虑将该程序推广到临床实践中,但数据仅限于小型病例系列,且未将未感染 HIV 的供体作为对照。方法在美国 26 个中心进行的一项观察性研究中,我们比较了将感染 HIV 的已故供体和未感染 HIV 的供体的肾脏移植给感染 HIV 的受体的情况。主要结果是安全事件(任何原因导致的死亡、移植物丢失、严重不良事件、HIV 突破性感染、HIV 治疗持续失败或机会性感染的综合结果),并进行了非劣效性评估(95% 置信区间的上限为 3.00)。次要结果包括总存活率、无移植物缺失存活率、排斥反应、感染、癌症和艾滋病病毒超级感染。结果我们招募了 408 名移植候选者,其中 198 人接受了已故捐赠者的肾脏;99 人接受了感染艾滋病病毒捐赠者的肾脏,99 人接受了未感染艾滋病病毒捐赠者的肾脏。综合主要结果的调整后危险比为 1.00(95% 置信区间 [CI],0.73 至 1.38),显示出非劣效性。以下次要结果与供体是否感染艾滋病相似:1 年(94% 对 95%)和 3 年(85% 对 87%)总存活率;1 年(93% 对 90%)和 3 年(84% 对 81%)无移植物丢失的存活率;1 年(13% 对 21%)和 3 年(21% 对 24%)排斥反应。两组严重不良事件、感染、手术或血管并发症以及癌症的发生率相似。HIV突破性感染的发生率在来自HIV捐献者肾脏的受者中更高(发生率比,3.14;95%,CI,1.02至9.63),在该组58名有序列数据的受者中,有一名潜在的HIV超级感染者,且没有持续的HIV治疗失败。(由美国国立过敏与传染病研究所资助;ClinicalTrials.gov 编号:NCT03500315)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
New England Journal of Medicine
New England Journal of Medicine 医学-医学:内科
CiteScore
145.40
自引率
0.60%
发文量
1839
审稿时长
1 months
期刊介绍: The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.
期刊最新文献
Atrasentan in Patients with IgA Nephropathy Crinecerfont in Adult Congenital Adrenal Hyperplasia Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC Rapid Cardiovascular Response to Belzutifan in HIF2A-Mediated Paraganglioma. How the Idea of Social Contagion Shaped Trans Medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1